Liberate Bio
1 known investors
Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
BiotechDeep TechDigital HealthMedical Devices
Founders & leadership
WS
Walter Strappsin
Investors · 1
Competitors · 2
by search overlap
elevatebio13 shared keywordsElevateBio is a cell and gene therapy technology company that operates cGMP manufacturing facilities (BaseCamp) and applies AI and CRISPR gene editing to develop genetic medicines and rare disease treatments. It provides manufacturing capacity and drug discovery capabilities to support cell and gene therapy companies bringing therapeutics to the clinic.
Bridgebio12 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Companies competing with Liberate Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Liberate Bio do?
- Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
- Who are Liberate Bio's investors?
- Liberate Bio's investors include Khosla Ventures.